ClinicalTrials.gg
Enrolling by invitationNCT07280572RECLAIMUpdated Dec 12, 2025

RECLAIM Adaptive Platform Trial for PCC Treatments

A Phase 3 interventional study of Metformin and colchicine in Post COVID Condition, sponsored by Janneke van de Wijgert. Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Janneke van de Wijgert · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.

Started
2025
with 1 other
Phase 3
3 of 15
3 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Janneke van de Wijgert

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 2 that started in 2025, is one of 3 in phase 3, and was the 12th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC). The trial started in the Netherlands in February 2025, comparing metformin, colchicine and usual care in an open-label domain. The information in this registration concerns that first domain in the Netherlands. A second domain, comparing minocyclin to a matching placebo, is expected to start in January 2026, also in the Netherlands. Trial-arms, additional domains and implementing countries may be introduced or terminated as the trial progresses. Participation is fully remote, using electronic consenting, video consultations and home delivery of medication. Default IP use is 12 weeks with biweekly online follow-up questionnaires between Day-1 and Week-12, and one final follow-up questionnaire at week-24.

03

Conditions studied

  • Post COVID Condition

Keywords

  • Post COVID condition
  • Clinical trial
  • Intervention
  • Repurposed drugs
  • Metformin
  • Colchicine
  • PAIS
  • Post Acute Sequelae of COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. Residing in the Netherlands (but excluding the Carribbean parts of the Netherlands) for the duration of trial participation.
  3. Persistent PCC symptoms, including fatigue and/or PEM, for a period of at least 12 weeks after the onset of a SARS-CoV-2 infection. The symptoms were not present prior to the infection, but may have partially subsided and resurged after the infection.
  4. Self-reported confirmation of having had a SARS-CoV-2 infection by:

    1. Positive SARS-CoV-2 nucleic acid amplification test, such as PCR;
    2. Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests;
    3. COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical tests and assessments.

    The above information will not be verified in medical records.

  5. Willing and able to provide .
  6. Willing and able to perform trial procedures.
  7. Allowing their GP/treating physicians/pharmacy and the RECLAIM trial team to exchange medical information that is relevant for the participant's safety and trial assessments.

Exclusion criteria

Exclusion criteria:

  1. Having been diagnosed with (exacerbation of) a chronic disease that can account for the onset of the PCC-like symptoms.
  2. Being hospitalized or institutionalized at screening. Patients can be rescreened after discharge.
  3. Presence of a serious medical condition that would prevent completion of follow-up.
  4. Currently enrolled, or having been enrolled within the last 30 days, in any other study where that study's interventions or procedures may affect RECLAIM outcomes or procedures. Individuals can be rescreened after at least 30 days have passed since participation in such a study has been completed.

    The following exclusion criteria will apply to all potential participants WITHIN ONE TRIAL DOMAIN (these patients may still qualify for another trial domain):

  5. The participant cannot be randomized to at least one IP arm and its control arm within a trial domain due to:

    1. Known to an active IP ingredient or IP/placebo ;
    2. Receiving a treatment that is to a trial IP;
    3. Already using a trial IP, or a drug in the same drug class as a trial IP, outside of the trial;
    4. Any other reason why a trial IP cannot be used, such as (risk of) pregnancy or breastfeeding or renal insufficiency.

During screening, these criteria will be assessed by licensed trial physicians. They will question the patient and verify prescription drug and use, and other medical exclusion criteria, in each individual patient's medical and/or pharmacy records. The absence of pregnancy in women of has to be confirmed by a negative urine or serum pregnancy test.

Additional IP-specific in- and exclusion criteria, if any, are listed in relevant treatment-specific appendices to the core protocol. These also describe the latest information about drug interactions and contraindications as per the IP's SmPC/PIL.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,250 participants (estimated)

Study arms

  • No intervention
    Usual care

    Participants receive their standard of care for PCC, without starting any new medications during study participation.

  • Experimental
    Metformin

    Drug: Metformin

  • Experimental
    Colchicine

    Drug: colchicine

Interventions

  • Participants receive metformin tablets for a period of 12-weeks.

  • Participants receive colchicine tablets for a period of 12-weeks.

06

What researchers measure

Primary outcomes

  1. Physical health-related quality of life (HRQoL)

    PROMIS-29 physical health summary score

    Time frame: 12 weeks

Secondary outcomes

  1. Mental HRQoL

    PROMIS-29 mental health summary score

    Time frame: 12 weeks

  2. Other aspects of HRQoL

    PROMIS-29 domain scores: physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, sleep disturbance.

    Time frame: 12 weeks

  3. Fatigue

    Checklist Individual Strength, fatigue severity subscale (CIS-8)

    Time frame: 12 weeks

  4. Post Exertional Malaise (PEM)

    DePaul Symptom Questionnaire (DSQ-2) PEM questions

    Time frame: 12 weeks

  5. Cognitive functioning

    PROMIS cognitive function 8a

    Time frame: 12 weeks

  6. Post Orthostatic Tachycardia Syndrome (POTS)

    DSQ-2 POTS questions

    Time frame: 12 weeks

  7. Safety of IPs

    Frequency of related and unrelated (S)AEs and SUSARs in each IP arm including their severity and outcome.

    Time frame: 12 weeks

  8. Tolerability of IPs

    Level of adherence to each IP. Percent of participants with adequate adherence for the specific IP.

    Time frame: 12 weeks

  9. Durability of IP treatment responses

    The proportion of participants that maintain HRQoL treatment success at 24 weeks.

    Time frame: 24 weeks

07

Study locations

1 site
  • Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Netherlands
    Utrecht, Netherlands
08

References and documents

Publications

  • van de Wijgert JHHM, Schoevers JMH, Swarthout TD, Bouwman WJT, van Rosmalen J, Leffelaar ER, Lalmohamed A, Loch C, van den Wijngaard CC, Prat-Aymerich C, Schotsman JJ, Verheijen ED, van der Bom JG, Bonten MJM. The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol. Trials. 2026 Feb 19;27(1):238. doi: 10.1186/s13063-026-09570-1. PubMed 41715140 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Feb 17, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07280572
Lead sponsor
Janneke van de Wijgert
Collaborators
European Clinical Research Alliance for Infectious Diseases (ECRAID)
Responsible party
Janneke van de Wijgert (Professor, UMC Utrecht) — Sponsor-investigator
First posted
Dec 12, 2025
Start date
Feb 17, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Colchicine

Start the discussion